Table 4.
Anti-angiogenic activity of isolated compounds in human EPCs
compound | IC50 (µM) a |
---|---|
1 | > 50 |
2 | > 50 |
3 | > 50 |
4 | > 50 |
5 | 5.6 ± 0.1 |
6 | > 50 |
7 | > 50 |
8 | 4.6 ± 0.1 |
9 | 8.1 ± 0.4 |
10 | 0.8 ± 0.3 |
11 | 5.2 ± 0.3 |
12 | 2.9 ± 0.3 |
13 | > 50 |
14 | > 50 |
Sorafenib b | 4.8 ± 0.3 |
aEPCs were treated with the indicated compounds for 48 h. Anti-angiogenic effects were evaluated in a cell growth assay (n = 3). Data are displayed as the mean ± SEM
bPositive control used in this study